Every Novo Nordisk weight-loss and diabetes medicine in one place: what is approved, what is in trials, what Novo has said lately, and what is scheduled next. Each line links to the page or source behind it.
Last checked . Company statements are labeled as company-reported. Looking for the other big company? See the Eli Lilly tracker.
Trial counts come from the Atlas trial tracker (ClinicalTrials.gov records, data of October 29, 2026). They include trials where a Novo medicine is the comparator, and many completed trials are counted. A registry entry describes a study, not a result.
| Company report
Novo Nordisk raised its 2026 outlook and listed its next milestones, including a U.S. decision on CagriSema in the fourth quarter of 2026. Details are in the log below. Next report: November 4, 2026.
| Competitor results
A Lilly-reported trial in type 2 diabetes that used Novo's highest Ozempic dose as the comparison.
| Approval
A higher-dose version of the weekly Wegovy injection.
| Filing
The first weekly amylin-plus-GLP-1 combination submitted for U.S. review.
Status is what the Atlas has verified. Trial counts are from the tracker, with the number still active in brackets. Counts overlap, because one trial can involve more than one medicine.
| Medicine | What it is | Where it stands | Trials (active) |
|---|---|---|---|
| Semaglutide (Wegovy, Wegovy HD, Wegovy pill, Ozempic, Rybelsus, Ozempic tablets) | GLP-1 medicine as a weekly injection or a daily tablet | Approved. Wegovy HD (7.2 mg) was approved in the U.S. on March 19, 2026. Novo's Q2 report also lists a U.S. decision on a 25 mg Ozempic tablet dose in the fourth quarter of 2026 and an FDA decision on a Wegovy pill filing for liver disease (MASH) in the first quarter of 2027. | 167 (20) |
| CagriSema | Once-weekly cagrilintide plus semaglutide injection | Not approved. Filed with the FDA on December 18, 2025. Novo's Q2 report lists a U.S. decision in the fourth quarter of 2026 and says the timing may change. | 12 (6) |
| Cagrilintide | Long-acting amylin injection | Investigational. Novo's Q2 report lists the start of a high-dose phase 3 trial in the fourth quarter of 2026. | 31 (12) |
| Zenagamtide (formerly amycretin, code NNC0487-0111) | One molecule that activates GLP-1 and amylin receptors, as a weekly injection or a daily tablet | Investigational, in phase 3 (the AMAZE program and a heart-failure outcomes trial). Not approved. | 23 (14) |
| UBT251 | Weekly injection that activates GLP-1, GIP and glucagon receptors. Discovered by The United Laboratories of China, with Novo holding rights outside Greater China | Investigational. Not approved. Two phase 2 trials were published in Cell Metabolism in October 2026 (read the summary). Novo is running its own phase 2 trials in obesity and type 2 diabetes, and the Chinese developer has phase 3 trials registered. Counts include trials run by the Chinese developer. | 11 (11) |
| Other early candidates | Novo development codes that begin with NNC | Early trials only. The Atlas has no medicine page for these yet. Novo's Q2 report says a triple-agonist entered a phase 2 trial and that development of monlunabant was terminated. | See the tracker |
Browse every trial, with filters, in the pipeline tracker. Compare medicines side by side in Compare. Pill or shot? See GLP-1 pill or shot.
The report is dated August 4, 2026 and covers the first half of the year. Everything below is company-reported and paraphrased from Novo's own filing. None of it is independent data, and none of it is investment advice.
| Topic | What was said |
|---|---|
| 2026 outlook | Novo raised its outlook. It now expects adjusted sales and adjusted operating profit to change by 0% to -6% at constant exchange rates, up from -4% to -12% in its May outlook, because it expects higher GLP-1 sales. |
| Wegovy pill | Second-quarter sales were DKK 3,218 million. Weekly prescriptions passed 265,000 in the week ending July 17, and total prescriptions since launch passed 5 million. Self-pay prices run from $149 to $299 a month depending on dose. The pill launched in the UAE in June and the UK in July, and received EU approval in July. |
| Wegovy injection and Wegovy HD | Second-quarter Wegovy injection sales were DKK 19,484 million. Wegovy 7.2 mg is approved in the U.S., UK and EU and launched in the U.S. in April. |
| Ozempic and Rybelsus | Second-quarter Ozempic sales were DKK 31,375 million. Sales of the tablet form (Rybelsus) were DKK 5,228 million. |
| CagriSema | A U.S. decision is listed for the fourth quarter of 2026. In the REIMAGINE 4 trial against tirzepatide in type 2 diabetes, Novo reports CagriSema met the weight-loss non-inferiority goal but not the HbA1c one. A high-dose phase 3 trial has started. |
| Zenagamtide | Phase 3 trials HF-POLARIS (heart failure outcomes) and AMAZE 8 have started. Novo expects AMAZE 8 to report in the first half of 2029 and HF-POLARIS in the second half of 2029. |
| U.S. list prices | From January 1, 2027, the list price of Wegovy and certain Ozempic doses will be cut to $675, about 50% lower for Wegovy and 35% lower for Ozempic. |
| Medicare | The Medicare Bridge pilot began July 1, 2026. See Medicare and GLP-1 medicines. |
| Legal | Novo says it sued Eli Lilly in July over false advertising. The Atlas has not reviewed that filing. |
Read the numbers in context: Ozempic vs Wegovy | Zepbound vs Wegovy | Compounded vs brand.
The Atlas links the originals so you can check us. Novo Nordisk investors | Novo news and IR materials | ClinicalTrials.gov.
New Novo Nordisk items appear in the Novo-only feed (RSS) within a day. Prefer everything? Use the full Atlas news feed. Following Eli Lilly too? There is a Lilly-only feed.
Semaglutide, sold as Wegovy (weekly injection), Wegovy HD (higher-dose weekly injection) and the Wegovy pill (daily tablet) for weight management, and as Ozempic and Rybelsus for type 2 diabetes. CagriSema and zenagamtide are investigational.
Novo filed it with the FDA on December 18, 2025, and its Q2 report lists a U.S. decision for the fourth quarter of 2026. That is the company's current timing and it can change. No approval exists yet.
The new name for amycretin, a single molecule that activates GLP-1 and amylin receptors. It is in phase 3 as a weekly injection and a daily tablet and is not approved. See zenagamtide (amycretin).
No. This page tracks company news and published trials. Ask a clinician about any medicine that might suit you.